Selpercatinib will expand treatment options available for people with RET fusion positive non small cell lung cancer on the NHS in England.
People who survive cancer in childhood have a higher risk of ill health as they grow older, according to new research published in The Lancet Regional Health – Europe.
Cancer Research UK presents charity collection in collaboration with influencer Shannon Alexandra at the Love Not Landfill fashion pop-up in London.
Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.
From snowy days in the country to festive wreaths and stockings, the shop has a design to suit every taste.
The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer.
The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland.
The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer.
In the last 6 years, almost 55,000 cancer patients should have been diagnosed or started their treatment sooner, according to new calculations.
Patients taking the drug trastuzumab deruxecan were 72% less likely to see their cancer grow significantly or to die than those on an existing breast cancer treatment.